Pharmacologic Therapy for Type 2 Diabetes Mellitus

Abstract

Letters4 July 2000Pharmacologic Therapy for Type 2 Diabetes MellitusRalph A. DeFronzo, MDRalph A. DeFronzo, MDUniversity of Texas Health Science Center at San Antonio; San Antonio, TX 78229 (DeFronzo)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-1-200007040-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:After publication of my article on therapy for type 2 diabetes (1), the Food and Drug Administration (FDA) withdrew troglitazone as monotherapy for the treatment of patients with this disease. The FDA has approved two new thiazolidinediones, rosiglitazone and pioglitazone, for this indication. A revised algorithm (Figure) takes into account these actions taken by the FDA.Figure.Revised pharmacologic algorithm for treatment of patients in whom type 2 diabetes is inadequately controlled with diet and exercise.FPG = fasting plasma glucose; HbA1c = hemoglobin A1c; HBGM = home blood glucose monitoring. * Goals and therapies must be individualized; † Preferred if patient is obese ...Reference1. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303. LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Texas Health Science Center at San Antonio; San Antonio, TX 78229 (DeFronzo) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPharmacolog…